These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 18502028

  • 1. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillén U, Strugala G.
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 3. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Lazzeri M.
    Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027
    [No Abstract] [Full Text] [Related]

  • 4. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT, Lee JZ, Lee YS, Yoon H, Park CH, Na YG, Jeong YB, Lee JB, Park WH.
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [Abstract] [Full Text] [Related]

  • 5. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Novara G.
    Eur Urol; 2009 Mar; 55(3):737. PubMed ID: 18502023
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rössler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Alloussi S, Bock P, Strugala G, Madersbacher H.
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [Abstract] [Full Text] [Related]

  • 8. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F, Vsetica J, Abadías M, Pavlík I, Schraml P, Brod'ák M, Villoria J, Sust M, E-4018/CL50 Study Group.
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [Abstract] [Full Text] [Related]

  • 9. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine].
    Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Brünjes R, Frank M, Wieners F.
    Aktuelle Urol; 2003 Mar; 34(2):102-8. PubMed ID: 14566693
    [Abstract] [Full Text] [Related]

  • 10. Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. Eur Urol 2009;55:729-38.
    Ates F, Akyol I, Cirakoglu A.
    Eur Urol; 2009 Jul; 56(1):e1; author reply e2. PubMed ID: 19056165
    [No Abstract] [Full Text] [Related]

  • 11. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
    Jünemann KP, Hessdörfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, Gramatté T.
    Urol Int; 2006 Jul; 77(4):334-9. PubMed ID: 17135784
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 14. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F, Stewart L, Dwyer P.
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [Abstract] [Full Text] [Related]

  • 15. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
    Jünemann KP, Halaska M, Rittstein T, Mürtz G, Schnabel F, Brünjes R, Nurkiewicz W.
    Eur Urol; 2005 Sep; 48(3):478-82. PubMed ID: 15967567
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M.
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T.
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [Abstract] [Full Text] [Related]

  • 18. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
    Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.
    Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
    [Abstract] [Full Text] [Related]

  • 19. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J, SUNRISE Study Group.
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [Abstract] [Full Text] [Related]

  • 20. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.